Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL
Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.
EP: 1.Navigating Frontline Treatment Options in CLL
EP: 2.Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting
EP: 3.Expert Perspectives on Extended Follow-Up Data from ALPINE
EP: 4.Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL
EP: 5.Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection
EP: 6.Treatment Strategies for Managing BTK Inhibitor Intolerance in CLL
EP: 7.Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL
This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.
Ujjani discusses emerging evidence on resistance to second-generation Bruton tyrosine kinase (BTK) inhibitors, focusing on zanubrutinib and acalabrutinib data. She notes growing data on mutations, primarily BTK C481, but highlights the need for more profiling and consistent assays. Furman mentions a study on a serine mutation, suggesting chronic lymphocytic leukemia (CLL) clones’ inherent ability to evolve, emphasizing the importance of using different agents.
Furman expresses gratitude for Ujjani’s insights and concludes the discussion. The conversation covers sequencing considerations, treatment algorithms, and the evolving understanding of CLL clone behavior. The dialogue provides valuable perspectives on BTK inhibitor resistance, emphasizing the need for tailored treatment approaches and continuous research for more robust data.
This summary was AI-generated and reviewed by OncLive® editorial staff.
